Response to alemtuzumab-based therapy and long-term survival after allogeneic transplantation in T-Cell prolymphocytic leukemia: a systematic review and meta-analysis of proportions.

In 30 seconds

This systematic review and meta-analysis evaluated the response to alemtuzumab-based therapy and long-term survival after allogeneic hematopoietic cell transplantation (allo-HCT) in adults with T-cell prolymphocytic leukemia (T-PLL). The analysis included seven studies with 200 patients, revealing a pooled overall response rate of 81.9% and a long-term survival rate of 30.3% after allo-HCT.

Key findings

• The pooled overall response rate to alemtuzumab-based therapy was 81.9% (95% CI 66.6-91.1).
• The complete response rate was 58.5% (95% CI 39.6-75.2).
• Long-term survival after allo-HCT was 30.3% (95% CI 25.8-35.3).
• Heterogeneity in response rates was noted based on the line of therapy.

Why it matters

Understanding the effectiveness of alemtuzumab-based therapy and the survival rates post-transplantation is crucial for clinicians managing T-PLL, a rare and aggressive leukemia. These findings provide benchmarks for treatment expectations and highlight the need for further research.